


Status: Currently Official on 17-Feb-2025
Official Date: Official as of 01-May-2020
Document Type: USP Monographs
DocId: GUID-8EE45C2A-0021-4B73-B910-A17F10250921_4_en-US
DOI: https://doi.org/10.31003/USPNF_M2795_04_01
DOI Ref: xr00g

© 2025 USPC
Do not distribute

Aminobenzoate Sodium



$C_7H_6NNaO_2$ 159.12
Benzoic acid, 4-amino-, sodium salt;
Sodium 4-aminobenzoate CAS RN®: 555-06-6; UNII: 75UI7QUZ5J.

DEFINITION
Aminobenzoate Sodium contains NLT 98.0% and NMT 102.0% of aminobenzoate sodium ($C_7H_6NNaO_2$), calculated on the dried basis.

IDENTIFICATION
Change to read:

- **A.** [▲SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Infrared Spectroscopy: 197K▲](#) (CN 1-MAY-2020)
- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.
- **C.** [IDENTIFICATION TESTS—GENERAL \(191\), Chemical Identification Tests, Sodium](#): A solution (1 in 100) meets the requirements of the flame test.

ASSAY

• **PROCEDURE**

Solution A: 1.5% acetic acid, prepared by mixing 690 mL of water with 10 mL of glacial acetic acid, and passing through a suitable filter of 0.45-µm pore size

Mobile phase: Methanol and *Solution A* (15:85)

Standard solution: 0.1 mg/mL of [USP Aminobenzoate Sodium RS](#) in *Mobile phase*. Sonicate to dissolve.

Sample solution: 0.1 mg/mL of Aminobenzoate Sodium in *Mobile phase*. Sonicate to dissolve.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 280 nm

Column: 3.0-mm × 15-cm; 3.5-µm packing L11

Flow rate: 0.35 mL/min

Injection volume: 5 µL

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 0.73%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of aminobenzoate sodium ($C_7H_6NNaO_2$) in the portion of Aminobenzoate Sodium taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of [USP Aminobenzoate Sodium RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Aminobenzoate Sodium in the *Sample solution* (mg/mL)

Acceptance criteria: 98.0%–102.0% on the dried basis

IMPURITIES

• LIMIT OF ANILINE AND *p*-TOLUIDINE

Diluent: Methylene chloride

Standard stock solution: 0.1 mg/mL each of [USP Aniline RS](#) and [USP *p*-Toluidine RS](#) in *Diluent*

Standard solution: 1.0 µg/mL each of [USP Aniline RS](#) and [USP *p*-Toluidine RS](#) in *Diluent* from *Standard stock solution*

Sample solution: 100 mg/mL of Aminobenzoate Sodium in *Diluent* prepared as follows. Add an appropriate quantity of Aminobenzoate Sodium to a suitable volumetric flask and dilute with *Diluent* to volume. Agitate for 10 min on a shaker and centrifuge at 3000 rpm for 5 min. Use the supernatant.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: GC

Detectors

Flame ionization: 300°

Hydrogen: 40 mL/min

Air: 400 mL/min

Column: 30-m × 0.32-mm fused silica capillary; coated with 0.5-µm film of phase G27

Temperatures

Injection port: 280°

Detector: 300°

Column: See [Table 1](#).

Table 1

Initial Temperature (°)	Temperature Ramp (°/min)	Final Temperature (°)	Hold Time at Final Temperature (min)
130	—	130	4
130	20	180	5

Carrier gas: Helium

Flow rate: 1 mL/min

Injection volume: 2 µL

Injection type: Split ratio, 1:10

System suitability

Sample: *Standard solution*

[NOTE—The relative retention times of aniline and *p*-toluidine are about 4.1 and 5.1 min, respectively.]

Suitability requirements

Resolution: NLT 7.0 between aniline and *p*-toluidine

Tailing factor: NMT 1.5 for aniline and *p*-toluidine

Relative standard deviation: NMT 6.0% for aniline and *p*-toluidine

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of *p*-toluidine or aniline in the portion of Aminobenzoate Sodium taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of *p*-toluidine or aniline from the *Sample solution*

r_S = peak response of *p*-toluidine or aniline from the *Standard solution*

C_S = concentration of the corresponding USP Reference Standard in the *Standard solution* (mg/mL)

C_U = concentration of Aminobenzoate Sodium in the *Sample solution* (mg/mL)

Acceptance criteria

Aniline: NMT 10 ppm

***p*-Toluidine:** NMT 20 ppm

• ORGANIC IMPURITIES

Solution A: 1.5% acetic acid, prepared by mixing 690 mL of water with 10 mL of glacial acetic acid

Solution B: Methanol

Table 2

Time (min)	Solution A (%)	Solution B (%)
0.0	85	15
4.0	85	15
4.1	45	55
10.0	45	55
10.1	85	15
13	85	15

Diluent: Methanol and water (85:15)

System suitability solution: 1 mg/mL of [USP Aminobenzoate Sodium RS](#), 0.01 mg/mL of [USP 4-Nitrobenzoic Acid RS](#), and 0.01 mg/mL of [USP Benzocaine RS](#) in *Diluent* prepared as follows. Transfer 1 mL each of 0.1 mg/mL of [USP 4-Nitrobenzoic Acid RS](#) in methanol and 0.1 mg/mL of [USP Benzocaine RS](#) in *Diluent* to a 10-mL volumetric flask containing the appropriate amount of [USP Aminobenzoate Sodium RS](#), and dilute with *Diluent* to volume.

Standard solution: 1 µg/mL each of [USP Aminobenzoate Sodium RS](#), [USP 4-Nitrobenzoic Acid RS](#), and [USP Benzocaine RS](#) in *Diluent*

Sample solution: 1 mg/mL of Aminobenzoate Sodium in *Diluent*

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 280 nm

Column: 3.0-mm × 15-cm; 3.5-µm packing L11

Flow rate: 0.4 mL/min

Injection volume: 5 µL

System suitability

Samples: *System suitability solution* and *Standard solution*

Suitability requirements

Resolution: NLT 1.5 between benzocaine and 4-nitrobenzoic acid, *System suitability solution*

Relative standard deviation: NMT 3% for the aminobenzoate sodium, 4-nitrobenzoic acid, and benzocaine peaks, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of 4-nitrobenzoic acid or benzocaine in the portion of Aminobenzoate Sodium taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of 4-nitrobenzoic acid or benzocaine from the *Sample solution*

r_S = peak response of 4-nitrobenzoic acid or benzocaine from the *Standard solution*

C_S = concentration of [USP 4-Nitrobenzoic Acid RS](#) or [USP Benzocaine RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Aminobenzoate Sodium in the *Sample solution* (mg/mL)

Calculate the percentage of any individual unspecified impurity in the portion of Aminobenzoate Sodium taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of any unspecified impurity from the *Sample solution*

r_S = peak response of aminobenzoate from the *Standard solution*

C_S = concentration of [USP Aminobenzoate Sodium RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Aminobenzoate Sodium in the *Sample solution* (mg/mL)

Table 3

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Aminobenzoic acid	1.0	—
Benzocaine	2.0	0.2
4-Nitrobenzoic acid	2.1	0.2
Any individual unspecified impurity	—	0.10

SPECIFIC TESTS

- [pH \(791\)](#)
Sample solution: 50 mg/mL
Acceptance criteria: 8.0–9.0
- [Loss on Drying \(731\)](#)
Analysis: Dry at 105° for 2 h.
Acceptance criteria: NMT 1.0%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in well-closed containers.
- [USP REFERENCE STANDARDS \(11\)](#)
[USP Aminobenzoate Sodium RS](#)
[USP Aniline RS](#)
Aniline.
 C_6H_7N 93.13
[USP Benzocaine RS](#)
[USP 4-Nitrobenzoic Acid RS](#)
4-Nitrobenzoic acid.
 $C_7H_5NO_4$ 167.12
[USP p-Toluidine RS](#)
4-Methylaniline.
 C_7H_9N 107.16

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
AMINO BENZOATE SODIUM	Documentary Standards Support	SM22020 Small Molecules 2
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	SM22020 Small Molecules 2

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 44(4)

Current DocID: GUID-8EE45C2A-0021-4B73-B910-A17F10250921_4_en-US

DOI: https://doi.org/10.31003/USPNF_M2795_04_01

DOI ref: [xr00g](#)